PharmaResearch Co Ltd
KOSDAQ:214450
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
89 100
259 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
PharmaResearch Co Ltd
Current Portion of Long-Term Debt
PharmaResearch Co Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Current Portion of Long-Term Debt
₩23.6B
|
CAGR 3-Years
71%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Current Portion of Long-Term Debt
₩175.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
27%
|
CAGR 10-Years
-1%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Current Portion of Long-Term Debt
₩8.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Green Cross Corp
KRX:006280
|
Current Portion of Long-Term Debt
₩31B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Current Portion of Long-Term Debt
₩2.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Current Portion of Long-Term Debt
₩88.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
297%
|
CAGR 10-Years
N/A
|
|
PharmaResearch Co Ltd
Glance View
In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.
See Also
What is PharmaResearch Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
23.6B
KRW
Based on the financial report for Sep 30, 2024, PharmaResearch Co Ltd's Current Portion of Long-Term Debt amounts to 23.6B KRW.
What is PharmaResearch Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
50%
Over the last year, the Current Portion of Long-Term Debt growth was 689%. The average annual Current Portion of Long-Term Debt growth rates for PharmaResearch Co Ltd have been 71% over the past three years , 50% over the past five years .
You don't have any saved screeners yet
